This is a tradename for trastizumab, one of the monoclonal antibody drugs used in treating early stage breast cancer in women with the her2 positive type of the disease about one in five of all those diagnosed. It is given, generally for one year, after other treatments such as chemotherapy, radiotherapy and/or surgery. It cannot be given to those with heart disease.